The synthesis of new purine derivatives designed to inhibit cell cycle regulating cyclin-dependent kinases (CDKs), is reported. These compounds, related to olomoucine and roscovitine, are characterised by the presence of a pyrrolidine methanol substituent at C-2 and a variety of ortho, meta and/or para substituents on the C-6 arylamino group.